José Luis A. R.
- Country
- Spain
- Department
- 1217:Oncología Médica
Research Overview
- Phase III Randomized Trial of Trastuzumab, Alpelisib, and Fulvestrant Versus Trastuzumab and Chemotherapy in PIK3CA-Mutated HER2+ Advanced Breast Cancer
- Evaluation of Ribociclib Combined with Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Phase III Randomized Trial
- Phase 3 Randomized Open-Label Study of OP-1250 Versus Standard of Care in ER+, HER2- Advanced or Metastatic Breast Cancer Post-Endocrine and CDK4/6 Inhibitor Therapy
Data & Insights
Has run more than one trial at 127 of 330 partner sites.
Specializations
Breast Cancer Specialization
The investigator focuses on advanced therapeutic approaches for various types of breast cancer, particularly hormone receptor-positive (HR+) and HER2-negative breast cancer. Their research encompasses both early-stage and metastatic disease states.
- Early-stage breast cancer treatment optimization
- Metastatic breast cancer management
- Hormone receptor-positive disease interventions
Novel Therapeutic Approaches
The investigator explores innovative treatment combinations including targeted therapies and endocrine therapy. Their work includes evaluation of new therapeutic agents for breast cancer treatment.
- Combination therapy strategies
- Targeted molecular treatments
- Endocrine therapy optimization
Advanced Cancer Research
Research interests extend to various types of advanced cancers, including solid tumors and specific conditions such as soft tissue sarcomas. The investigator studies treatment approaches for both localized and metastatic disease.
- Metastatic solid tumor treatment
- Brain metastases management
- Sarcoma therapeutic interventions
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.